{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T03:34:16Z","timestamp":1773804856875,"version":"3.50.1"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.yebeh.2020.107502","type":"journal-article","created":{"date-parts":[[2020,12,13]],"date-time":"2020-12-13T11:02:31Z","timestamp":1607857351000},"page":"107502","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Association between antiseizure medication use and risk of urinary tract infection: A case\u2013control study"],"prefix":"10.1016","volume":"115","author":[{"given":"Jana","family":"Heidemann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bettina","family":"Schmitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karel","family":"Kostev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2020.107502_bb0005","series-title":"Epilepsy","first-page":"1","author":"World Health Organisation","year":"2019"},{"key":"10.1016\/j.yebeh.2020.107502_bb0010","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1101\/cshperspect.a022426","article-title":"Seizures and epilepsy: an overview","volume":"5","author":"Stafstrom","year":"2015","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.yebeh.2020.107502_bb0015","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S1474-4422(18)30454-X","article-title":"Global, regional, and national burden of epilepsy, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"18","author":"Beghi","year":"2019","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.yebeh.2020.107502_bb0020","first-page":"612","article-title":"From wonder and fear: make epilepsy a global health priority","volume":"393","author":"The Lancet","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.yebeh.2020.107502_bb0025","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.phrs.2016.03.016","article-title":"The challenges of treating epilepsy with 25 antiepileptic drugs","volume":"107","author":"Santulli","year":"2016","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.yebeh.2020.107502_bb0030","first-page":"508","article-title":"Update about antiepileptic drugs \u2014 2019","volume":"25","author":"Abou-Khalil","year":"2019","journal-title":"Contin (Minneap Minn)"},{"key":"10.1016\/j.yebeh.2020.107502_bb0035","doi-asserted-by":"crossref","first-page":"205","DOI":"10.2176\/nmc.ra.2015-0344","article-title":"The new antiepileptic drugs: their neuropharmacology and clinical indications","volume":"56","author":"Hanaya","year":"2016","journal-title":"Neurol Med Chir (Tokyo)"},{"key":"10.1016\/j.yebeh.2020.107502_bb0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fnins.2019.00721","article-title":"Ferroptosis induction in pentylenetetrazole kindling and pilocarpine-induced epileptic seizures in mice","volume":"13","author":"Mao","year":"2019","journal-title":"Front Neurosci"},{"key":"10.1016\/j.yebeh.2020.107502_bb0045","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.pharmthera.2019.05.010","article-title":"An update for epilepsy research and antiepileptic drug development: toward precise circuit therapy","volume":"201","author":"Wang","year":"2019","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.yebeh.2020.107502_bb0050","first-page":"142","article-title":"Anticonvulsant activity: an overview introduction","volume":"1","author":"Wagh","year":"2011","journal-title":"Jpsbr"},{"key":"10.1016\/j.yebeh.2020.107502_bb0055","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1111\/bcp.13296","article-title":"Do antiepileptic drugs increase the risk of infectious diseases? A meta-analysis of placebo-controlled studies","volume":"83","author":"Zaccara","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.yebeh.2020.107502_bb0060","doi-asserted-by":"crossref","first-page":"303","DOI":"10.2165\/00002018-200022040-00003","article-title":"The tolerability of lamotrigine in children","volume":"22","author":"Messenheimer","year":"2000","journal-title":"Drug Saf"},{"key":"10.1016\/j.yebeh.2020.107502_bb0065","doi-asserted-by":"crossref","first-page":"627","DOI":"10.3109\/00207454.2013.866951","article-title":"The adverse effects profile of levetiracetam in epilepsy: a more detailed look","volume":"124","author":"Mbizvo","year":"2014","journal-title":"Int J Neurosci"},{"key":"10.1016\/j.yebeh.2020.107502_bb0070","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/cns.12418","article-title":"Zonisamide: review of recent clinical evidence for treatment of epilepsy","volume":"21","author":"Kwan","year":"2015","journal-title":"CNS Neurosci Ther"},{"key":"10.1016\/j.yebeh.2020.107502_bb0075","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/ane.12044","article-title":"Reduced immunoglobulin levels in epilepsy patients treated with levetiracetam, lamotrigine, or carbamazepine","volume":"127","author":"Svalheim","year":"2013","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.yebeh.2020.107502_bb0080","doi-asserted-by":"crossref","first-page":"496","DOI":"10.5414\/CP203320","article-title":"Basic characteristics and representativeness of the German Disease Analyzer database","volume":"56","author":"Rathmann","year":"2018","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.yebeh.2020.107502_bb0085","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.diabet.2015.07.002","article-title":"Urinary and genital infections in patients with diabetes: how to diagnose and how to treat","volume":"42","author":"Njomnang Soh","year":"2016","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.yebeh.2020.107502_bb0090","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1080\/00325481.2015.1018799","article-title":"Benign prostatic hyperplasia and urinary symptoms: evaluation and treatment","volume":"127","author":"Mobley","year":"2015","journal-title":"Postgrad Med"},{"key":"10.1016\/j.yebeh.2020.107502_bb0095","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.seizure.2018.04.015","article-title":"Evaluating the longer-term cognitive effects of adjunctive perampanel compared to lacosamide in a naturalistic outpatient setting","volume":"58","author":"Meschede","year":"2018","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2020.107502_bb0100","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1177\/1756285611417920","article-title":"The cognitive impact of antiepileptic drugs","volume":"4","author":"Eddy","year":"2011","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.yebeh.2020.107502_bb0105","first-page":"S330","article-title":"Antiepileptic drugs: a consideration of clinical and biochemical outcome in patients with epilepsy","volume":"4","author":"Tolou-Ghamari","year":"2013","journal-title":"Int J Prev Med"},{"key":"10.1016\/j.yebeh.2020.107502_bb0110","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/j.1528-1167.2011.03035.x","article-title":"Antiepileptic drugs and the immune system","volume":"52","author":"Beghi","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2020.107502_bb0115","first-page":"799","article-title":"Effects of aniepileptic drugs on immune system","volume":"65","author":"Basta-Kaim","year":"2008","journal-title":"Przegl Lek"},{"key":"10.1016\/j.yebeh.2020.107502_bb0120","first-page":"908","article-title":"Adverse effects of antiepileptic drugs","volume":"72","author":"Takahashi","year":"2014","journal-title":"Nihon Rinsho"},{"key":"10.1016\/j.yebeh.2020.107502_bb0125","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/S1734-1140(10)70317-0","article-title":"Immunological aspects of epilepsy","volume":"62","author":"Zarczuk","year":"2010","journal-title":"Pharmacol Rep"},{"key":"10.1016\/j.yebeh.2020.107502_bb0130","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/j.1600-0404.1982.tb04514.x","article-title":"The effect of carbamazepine on serum immunoglobulin concentrations","volume":"66","author":"Gilhus","year":"1982","journal-title":"Acta Neruol Scand"},{"key":"10.1016\/j.yebeh.2020.107502_bb0135","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/0192-0561(94)90087-6","article-title":"Humoral and cellular immune parameters in untreated and phenytoin- or carbamazepine-treated epileptic patients","volume":"16","author":"Ba\u015faran","year":"1994","journal-title":"Int J Immunopharmacol"},{"key":"10.1016\/j.yebeh.2020.107502_bb0140","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1080\/00365540260348662","article-title":"Reversible panhypogammaglobulinemia associated with phenytoin treatment","volume":"34","author":"Pereira","year":"2002","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.yebeh.2020.107502_bb0145","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.seizure.2011.12.013","article-title":"Carbamazepine-induced hypogammaglobulinemia","volume":"21","author":"Ozaras","year":"2012","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2020.107502_bb0150","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1007\/s10072-012-1153-3","article-title":"Valproate-induced panhypogammaglobulinemia","volume":"34","author":"Eom","year":"2013","journal-title":"Neurol Sci"},{"key":"10.1016\/j.yebeh.2020.107502_bb0155","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1136\/adc.57.9.681","article-title":"Valproic acid and immune thrombocytopenia","volume":"57","author":"Barr","year":"1982","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.yebeh.2020.107502_bb0160","first-page":"273","article-title":"Depression of immune competence by phenytoin and carbamazepine. Studies in vivo and in vitro","volume":"20","author":"Sorrell","year":"1975","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.yebeh.2020.107502_bb0165","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1177\/096032718500400205","article-title":"Effect of chronic anticonvulsant monotherapy on lymphocyte subpopulations in adult epileptic patients","volume":"4","author":"Marcoli","year":"1985","journal-title":"Hum Exp Toxicol"},{"key":"10.1016\/j.yebeh.2020.107502_bb0170","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1046\/j.1365-2249.2003.02097.x","article-title":"Immunoglobulins in children with epilepsy: the Dutch study of epilepsy in childhood","volume":"132","author":"Callenbach","year":"2003","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.yebeh.2020.107502_bb0175","series-title":"Manag. Antimicrob. Infect. Dis. illustrate","first-page":"315","article-title":"Infections in the immunocompromised host","author":"Morrison","year":"2000"},{"key":"10.1016\/j.yebeh.2020.107502_bb0180","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1600-0404.2011.01539.x","article-title":"Haematological side effects of antiepileptic drug treatment in patients with epilepsy","volume":"124","author":"Bachmann","year":"2011","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.yebeh.2020.107502_bb0185","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1136\/pgmj.33.379.242","article-title":"Megaloblastic anaemia associated with anticonvulsant drug therapy","volume":"33","author":"Forshaw","year":"1957","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.yebeh.2020.107502_bb0190","first-page":"183","article-title":"Megaloblastic anemia following the use of primidone","volume":"12","author":"Newman","year":"1957","journal-title":"Am Soc Hematol"},{"key":"10.1016\/j.yebeh.2020.107502_bb0195","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1001\/jama.1957.82970460003008a","article-title":"Megaloblastic anemia during primidone (Mysoline) therapy","volume":"163","author":"Christenson","year":"1957","journal-title":"JAMA"},{"key":"10.1016\/j.yebeh.2020.107502_bb0200","series-title":"Atlas Hematop. annotated","first-page":"885","article-title":"Disorders of red blood cells: anemias","author":"Naeim","year":"2012"},{"key":"10.1016\/j.yebeh.2020.107502_bb0205","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3949\/ccjm.87a.19072","article-title":"Severe megaloblastic anemia: vitamin deficiency and other causes","volume":"87","author":"Socha","year":"2020","journal-title":"Cleve Clin J Med"},{"key":"10.1016\/j.yebeh.2020.107502_bb0210","series-title":"Blutkrankheiten. Gesundheits- und Krankheitslehre","first-page":"139","author":"Beise","year":"2009"},{"key":"10.1016\/j.yebeh.2020.107502_bb0215","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1007\/s10072-014-1701-0","article-title":"Anticonvulsant drugs and hematological disease","volume":"35","author":"Verrotti","year":"2014","journal-title":"Neurol Sci"},{"key":"10.1016\/j.yebeh.2020.107502_bb0220","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1542\/peds.32.3.376","article-title":"Megaloblastic anemia associated with the ingestion of phenobarbital and primidone","volume":"32","author":"Kahn","year":"1963","journal-title":"Pediatrics"},{"key":"10.1016\/j.yebeh.2020.107502_bb0225","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/0002-9343(60)90170-4","article-title":"Megaloblastic anemia associated with anticonvulsant drugs","volume":"28","author":"Flexner","year":"1960","journal-title":"Am J Med"},{"key":"10.1016\/j.yebeh.2020.107502_bb0230","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.hgmx.2015.07.001","article-title":"Megaloblastic anaemia: folic acid and vitamin B12 metabolism","volume":"78","author":"Castellanos-Sinco","year":"2015","journal-title":"Rev M\u00e9dica Del Hosp Gen M\u00e9xico"},{"key":"10.1016\/j.yebeh.2020.107502_bb0235","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1056\/NEJMra1508861","article-title":"Drug-induced megaloblastic anemia","volume":"373","author":"Hesdorffer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.yebeh.2020.107502_bb0240","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1752-1947-6-239","article-title":"Anemia secondary to valproic acid therapy in a 13-year-old boy: a case report","volume":"6","author":"Kaczorowska-Hac","year":"2012","journal-title":"J Med Case Rep"},{"key":"10.1016\/j.yebeh.2020.107502_bb0245","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1080\/17474086.2017.1271319","article-title":"Thrombocytopenia and infections","volume":"10","author":"Franchini","year":"2017","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.yebeh.2020.107502_bb0250","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40268-017-0224-6","article-title":"The risk of thrombocytopenia during valproic acid therapy: a critical summary of available clinical data","volume":"18","author":"Buoli","year":"2018","journal-title":"Drugs R D"},{"key":"10.1016\/j.yebeh.2020.107502_bb0255","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1097\/JCP.0b013e3181c97c29","article-title":"Oxcarbazepine-related neutropenia: a case report","volume":"30","author":"Hsiao","year":"2010","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.yebeh.2020.107502_bb0260","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/JCP.0b013e3182051913","article-title":"Oxcarbazepine-related thrombocytopenic purpura","volume":"31","author":"He","year":"2011","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.yebeh.2020.107502_bb0265","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1176\/jnp.2008.20.4.502","article-title":"Oxcarbazepine-induced leukopenia","volume":"20","author":"Milia","year":"2008","journal-title":"J Neuropsychiatr Clin Neurosci"},{"key":"10.1016\/j.yebeh.2020.107502_bb0270","series-title":"Princ. Pract. Stereotact. Radiosurgery","first-page":"331","article-title":"Pediatric radiosurgery","author":"Reisner","year":"2010"},{"key":"10.1016\/j.yebeh.2020.107502_bb0275","doi-asserted-by":"crossref","first-page":"312","DOI":"10.3345\/kjp.2019.00017","article-title":"Evaluation of hematologic profile may be needed for patients treated with oxcarbazepine","volume":"62","author":"Hyun Jung","year":"2019","journal-title":"Korean J Pediatr"},{"key":"10.1016\/j.yebeh.2020.107502_bb0280","first-page":"622","article-title":"Gabapentin-induced neutropenia: a case report","volume":"27","author":"Lee","year":"2003","journal-title":"J Korean Acad Rehabil Med"},{"key":"10.1016\/j.yebeh.2020.107502_bb0285","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.clon.2004.06.015","article-title":"Neutropenia occurring after starting gabapentin for neuropathic pain","volume":"16","author":"Derbyshire","year":"2004","journal-title":"Clin Oncol"},{"key":"10.1016\/j.yebeh.2020.107502_bb0290","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1136\/bmj.293.6547.627-a","article-title":"Management of infection in the neutropenic patient","volume":"293","author":"Hardie","year":"1986","journal-title":"Br Med J"},{"key":"10.1016\/j.yebeh.2020.107502_bb0295","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1212\/WNL.0b013e318207b073","article-title":"Adverse antiepileptic drug effects in new-onset seizures: a case\u2013control study","volume":"76","author":"Perucca","year":"2011","journal-title":"Neurology"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152550502030682X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152550502030682X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:41:49Z","timestamp":1761504109000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152550502030682X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":59,"alternative-id":["S152550502030682X"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2020.107502","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association between antiseizure medication use and risk of urinary tract infection: A case\u2013control study","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2020.107502","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107502"}}